Early treatment with ambrisentan of mildly elevated mean pulmonary arterial pressure associated with systemic sclerosis: a randomized, controlled, double-blind, parallel group study (EDITA study)

The objective of this randomized, placebo-controlled, double-blind, parallel group, trial was to assess the effect of ambrisentan on mean pulmonary arterial pressure (mPAP) in patients with systemic sclerosis (SSc) and mildly elevated pulmonary hypertension (PH).

Bibliographic Details

Main Authors:	Pan, Zixuan (Author) , Benjamin, Nicola (Author) , Eichstaedt, Christina (Author) , Blank, Norbert (Author) , Egenlauf, Benjamin (Author) , Fischer, Christine (Author) , Harutyunova, Satenik (Author) , Xanthouli, Panagiota (Author) , Lorenz, Hanns-Martin (Author) , Grünig, Ekkehard (Author)
Format:	Article (Journal)
Language:	English
Published:	26 October 2019
In:	Arthritis Research & Therapy Year: 2019, Volume: 21
ISSN:	1465-9913
DOI:	10.1186/s13075-019-1981-0
Online Access:	Verlag, Volltext: https://doi.org/10.1186/s13075-019-1981-0
Author Notes:	Zixuan Pan, Alberto M. Marra, Nicola Benjamin, Christina A. Eichstaedt, Norbert Blank, Eduardo Bossone, Antonio Cittadini, Gerry Coghlan, Christopher P. Denton, Oliver Distler, Benjamin Egenlauf, Christine Fischer, Satenik Harutyunova, Panagiota Xanthouli, Hanns-Martin Lorenz, Ekkehard Grünig